The Experts below are selected from a list of 1344 Experts worldwide ranked by ideXlab platform
Ifeyinwa Osunkwo - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis:
Hospital Pharmacy, 2020Co-Authors: Katherine Rector, Shelby Merchant, Rachel Crawford, Justin R. Arnall, James T. Symanowski, Padmaja Veeramreddy, Ifeyinwa OsunkwoAbstract:Purpose: To compare the incidence of Oversedation between oral and parenteral diphenhydramine therapy for treatment of opioid-induced pruritus in patients with sickle cell disease vaso-occlusive cr...
-
Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis
Blood, 2018Co-Authors: Ifeyinwa Osunkwo, Katherine Rector, Shelby Merchant, Rachel Crawford, Justin R. Arnall, James T. Symanowski, Padmaja VeeramreddyAbstract:Inpatient management of sickle cell disease (SCD) vaso-occlusive crisis (VOC) often involves use of high-dose opioids, which may result in opioid-induced pruritus (OIP). This OIP is typically treated with antihistamines like diphenhydramine either orally or intravenously. The Oversedation adverse effects of diphenhydramine may be magnified when given in combination with high-dose opioid therapy. Current recommendations made by the National Heart, Lung, and Blood Institute endorse using oral rather than intravenous (IV) antihistamines to avoid the cumulative effect on sedation. Despite this guideline, IV diphenhydramine use is still prevalent in many hospitals that treat persons with SCD. We performed a retrospective, single-center, cohort study comparing rates of Oversedation among patients who received IV and oral diphenhydramine for management of opioid-induced pruritus in a large SCD inpatient population. Patients with SCD VOC admitted to an urban hospital between June 1, 2016 to July 30, 2017 were included if they were ≥ 18 years old and received either IV or oral diphenhydramine for OIP. Exclusion criteria: Pregnancy, received Disclosures Osunkwo:Terumo BCT: Speakers Bureau; Prolog Pharmaceuticals LLC: Consultancy; Novartis Pharmaceuticals LLC: Consultancy, Speakers Bureau. Symanowski:Immatics: Other: Data Safety Monitoring Board; Eli Lily & Co: Other: Data Safety Monitoring Board; Boston Biomedical: Other: Data Safety Monitoring Board ; Five Prime Therapeutics: Other: Data Safety Monitoring Board .
Padmaja Veeramreddy - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis:
Hospital Pharmacy, 2020Co-Authors: Katherine Rector, Shelby Merchant, Rachel Crawford, Justin R. Arnall, James T. Symanowski, Padmaja Veeramreddy, Ifeyinwa OsunkwoAbstract:Purpose: To compare the incidence of Oversedation between oral and parenteral diphenhydramine therapy for treatment of opioid-induced pruritus in patients with sickle cell disease vaso-occlusive cr...
-
Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis
Blood, 2018Co-Authors: Ifeyinwa Osunkwo, Katherine Rector, Shelby Merchant, Rachel Crawford, Justin R. Arnall, James T. Symanowski, Padmaja VeeramreddyAbstract:Inpatient management of sickle cell disease (SCD) vaso-occlusive crisis (VOC) often involves use of high-dose opioids, which may result in opioid-induced pruritus (OIP). This OIP is typically treated with antihistamines like diphenhydramine either orally or intravenously. The Oversedation adverse effects of diphenhydramine may be magnified when given in combination with high-dose opioid therapy. Current recommendations made by the National Heart, Lung, and Blood Institute endorse using oral rather than intravenous (IV) antihistamines to avoid the cumulative effect on sedation. Despite this guideline, IV diphenhydramine use is still prevalent in many hospitals that treat persons with SCD. We performed a retrospective, single-center, cohort study comparing rates of Oversedation among patients who received IV and oral diphenhydramine for management of opioid-induced pruritus in a large SCD inpatient population. Patients with SCD VOC admitted to an urban hospital between June 1, 2016 to July 30, 2017 were included if they were ≥ 18 years old and received either IV or oral diphenhydramine for OIP. Exclusion criteria: Pregnancy, received Disclosures Osunkwo:Terumo BCT: Speakers Bureau; Prolog Pharmaceuticals LLC: Consultancy; Novartis Pharmaceuticals LLC: Consultancy, Speakers Bureau. Symanowski:Immatics: Other: Data Safety Monitoring Board; Eli Lily & Co: Other: Data Safety Monitoring Board; Boston Biomedical: Other: Data Safety Monitoring Board ; Five Prime Therapeutics: Other: Data Safety Monitoring Board .
Matthijs Hoog - One of the best experts on this subject based on the ideXlab platform.
-
Optimal sedation in pediatric intensive care patients: a systematic review
Intensive Care Medicine, 2013Co-Authors: Nienke J. Vet, Erwin Ista, Saskia N. Wildt, Monique Dijk, Dick Tibboel, Matthijs HoogAbstract:Purpose Sedatives administered to critically ill children should be titrated to effect, because both under- and Oversedation may have negative effects. We conducted a systematic review to examine reported incidences of under-, optimal, and Oversedation in critically ill children receiving intensive care. Methods A systematic literature search using predefined criteria was performed in PubMed and Embase to identify all articles evaluating level of sedation in PICU patients receiving continuous sedation. Two authors independently recorded: study objective, study design, sample size, age range, details of study intervention (if applicable), sedatives used, length of sedation, sedation scale used, and incidences of optimal, under-, and Oversedation as defined in the studies. Results Twenty-five studies were included. Two studies evaluated sedation level as primary study outcome; the other 23 as secondary outcomes. Together, these studies investigated 1,163 children; age range, 0–18 years. Across studies, children received many different sedative agents and sedation level was assessed with 12 different sedation scales. Optimal sedation was ascertained in 57.6 % of the observations, under sedation in 10.6 %, and Oversedation in 31.8 %. Conclusions This study suggests that sedation in the PICU is often suboptimal and seldom systematically evaluated. Oversedation is more common than undersedation. As Oversedation may lead to longer hospitalization, tolerance, and withdrawal, preventing Oversedation in pediatric intensive care deserves greater attention.
-
Optimal sedation in pediatric intensive care patients: A systematic review
'Springer Science and Business Media LLC', 2013Co-Authors: Vet N.j., Saskia N. Wildt, Ista E., Dijk M. Van, Tibboel D., Matthijs HoogAbstract:Purpose: Sedatives administered to critically ill children should be titrated to effect, because both under- and Oversedation may have negative effects. We conducted a systematic review to examine reported incidences of under-, optimal, and Oversedation in critically ill children receiving intensive care. Methods: A systematic literature search using predefined criteria was performed in PubMed and Embase to identify all articles evaluating level of sedation in PICU patients receiving continuous sedation. Two authors independently recorded: study objective, study design, sample size, age range, details of study intervention (if applicable), sedatives used, length of sedation, sedation scale used, and incidences of optimal, under-, and Oversedation as defined in the studies. Results: Twenty-five studies were included. Two studies evaluated sedation level as primary study outcome; the other 23 as secondary outcomes. Together, these studies investigated 1,163 children; age range, 0-18 years. Across studies, children received many different sedative agents and sedation level was assessed with 12 different sedation scales. Optimal sedation was ascertained in 57.6 % of the observations, under sedation i
-
Optimal sedation in pediatric intensive care patients: a systematic review
Intensive Care Medicine, 2013Co-Authors: Nienke J. Vet, Erwin Ista, Saskia N. Wildt, Dick Tibboel, Monique Van Dijk, Matthijs HoogAbstract:Purpose Sedatives administered to critically ill children should be titrated to effect, because both under- and Oversedation may have negative effects. We conducted a systematic review to examine reported incidences of under-, optimal, and Oversedation in critically ill children receiving intensive care.
Katherine Rector - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis:
Hospital Pharmacy, 2020Co-Authors: Katherine Rector, Shelby Merchant, Rachel Crawford, Justin R. Arnall, James T. Symanowski, Padmaja Veeramreddy, Ifeyinwa OsunkwoAbstract:Purpose: To compare the incidence of Oversedation between oral and parenteral diphenhydramine therapy for treatment of opioid-induced pruritus in patients with sickle cell disease vaso-occlusive cr...
-
Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis
Blood, 2018Co-Authors: Ifeyinwa Osunkwo, Katherine Rector, Shelby Merchant, Rachel Crawford, Justin R. Arnall, James T. Symanowski, Padmaja VeeramreddyAbstract:Inpatient management of sickle cell disease (SCD) vaso-occlusive crisis (VOC) often involves use of high-dose opioids, which may result in opioid-induced pruritus (OIP). This OIP is typically treated with antihistamines like diphenhydramine either orally or intravenously. The Oversedation adverse effects of diphenhydramine may be magnified when given in combination with high-dose opioid therapy. Current recommendations made by the National Heart, Lung, and Blood Institute endorse using oral rather than intravenous (IV) antihistamines to avoid the cumulative effect on sedation. Despite this guideline, IV diphenhydramine use is still prevalent in many hospitals that treat persons with SCD. We performed a retrospective, single-center, cohort study comparing rates of Oversedation among patients who received IV and oral diphenhydramine for management of opioid-induced pruritus in a large SCD inpatient population. Patients with SCD VOC admitted to an urban hospital between June 1, 2016 to July 30, 2017 were included if they were ≥ 18 years old and received either IV or oral diphenhydramine for OIP. Exclusion criteria: Pregnancy, received Disclosures Osunkwo:Terumo BCT: Speakers Bureau; Prolog Pharmaceuticals LLC: Consultancy; Novartis Pharmaceuticals LLC: Consultancy, Speakers Bureau. Symanowski:Immatics: Other: Data Safety Monitoring Board; Eli Lily & Co: Other: Data Safety Monitoring Board; Boston Biomedical: Other: Data Safety Monitoring Board ; Five Prime Therapeutics: Other: Data Safety Monitoring Board .
Shelby Merchant - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis:
Hospital Pharmacy, 2020Co-Authors: Katherine Rector, Shelby Merchant, Rachel Crawford, Justin R. Arnall, James T. Symanowski, Padmaja Veeramreddy, Ifeyinwa OsunkwoAbstract:Purpose: To compare the incidence of Oversedation between oral and parenteral diphenhydramine therapy for treatment of opioid-induced pruritus in patients with sickle cell disease vaso-occlusive cr...
-
Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis
Blood, 2018Co-Authors: Ifeyinwa Osunkwo, Katherine Rector, Shelby Merchant, Rachel Crawford, Justin R. Arnall, James T. Symanowski, Padmaja VeeramreddyAbstract:Inpatient management of sickle cell disease (SCD) vaso-occlusive crisis (VOC) often involves use of high-dose opioids, which may result in opioid-induced pruritus (OIP). This OIP is typically treated with antihistamines like diphenhydramine either orally or intravenously. The Oversedation adverse effects of diphenhydramine may be magnified when given in combination with high-dose opioid therapy. Current recommendations made by the National Heart, Lung, and Blood Institute endorse using oral rather than intravenous (IV) antihistamines to avoid the cumulative effect on sedation. Despite this guideline, IV diphenhydramine use is still prevalent in many hospitals that treat persons with SCD. We performed a retrospective, single-center, cohort study comparing rates of Oversedation among patients who received IV and oral diphenhydramine for management of opioid-induced pruritus in a large SCD inpatient population. Patients with SCD VOC admitted to an urban hospital between June 1, 2016 to July 30, 2017 were included if they were ≥ 18 years old and received either IV or oral diphenhydramine for OIP. Exclusion criteria: Pregnancy, received Disclosures Osunkwo:Terumo BCT: Speakers Bureau; Prolog Pharmaceuticals LLC: Consultancy; Novartis Pharmaceuticals LLC: Consultancy, Speakers Bureau. Symanowski:Immatics: Other: Data Safety Monitoring Board; Eli Lily & Co: Other: Data Safety Monitoring Board; Boston Biomedical: Other: Data Safety Monitoring Board ; Five Prime Therapeutics: Other: Data Safety Monitoring Board .
